Lizenz: Creative Commons Namensnennung 4.0 International PDF - Veröffentlichte Version (2MB) |
- URN zum Zitieren dieses Dokuments:
- urn:nbn:de:bvb:355-epub-543744
- DOI zum Zitieren dieses Dokuments:
- 10.5283/epub.54374
Zusammenfassung
Chimeric antigen receptor (CAR) modified T cells can induce complete remissions in patients with advanced hematological malignancies. Nevertheless, the efficacy is mostly transient and remains so far poor in the treatment of solid tumors. Crucial barriers to long-term CAR T cell success encompass loss of functional capacities known as “exhaustion”, among others. To extend CAR T cell ...
Nur für Besitzer und Autoren: Kontrollseite des Eintrags